



ADVISORY

No. 240-a

February 9, 2022

Coverage of Oral Antivirals for the Treatment of COVID-19

Effective February 17, 2022, the Office of Pharmacy Services (OPS) will cover pharmacy claims of oral antivirals approved or granted Emergency Use Authorization (EUA) by the FDA for the treatment of COVID-19 for Fee-For-Service (FFS) participants. Currently, the two FDA-authorized oral antivirals are [Paxlovid](#) (Nirmatrelvir and ritonavir) and [Molnupiravir](#).

Under the EUA, these products will be reimbursed with an ingredient cost of \$ 0.01 and a professional dispensing fee of \$ 10.67. Participant copayments will not apply.

Updated COVID-19 payer specific information with instructions on how to submit a claim is available at <http://www.mdrxprograms.com/ooep.html#PSI>

Please visit our website for additional information:

<https://health.maryland.gov/mmcp/pap/Pages/paphome.aspx>

In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH) **Office of Pharmacy Services (OPS)** has developed the **Maryland Medicaid Pharmacy Program Advisory**.

To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations.

It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the OPS representative at 410-767-1455